Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
Authors:
Top Cited Papers
- 1 May 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 78 (5) , 558-567
Abstract
Multiple sclerosis (MS), a chronic autoimmune disease of the central nervous system, is clinically perceived by relapses and progressive loss of neurological function, primarily attributed to inflammatory attacks leading to demyelination, axonal loss, and gliosis culminating in long-term multifocal sclerotic plaques in the brain and spinal cord.1-3 Oral disease-modifying therapy (DMT) options such as teriflunomide,4,5 fingolimod,6 dimethyl fumarate,7,8 and siponimod9 have broadened disease management options in MS. Despite significant progress in MS therapy, there is still an unmet need for effective, safe, and convenient treatments that can be used early in the disease course.10-12 Given the number of alternative options of oral treatments, head-to-head comparative trials to inform choices are still lacking.13Keywords
This publication has 41 references indexed in Scilit:
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple SclerosisNew England Journal of Medicine, 2012
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple SclerosisNew England Journal of Medicine, 2011
- The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue InflammationThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor NomenclaturePharmacological Reviews, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- A graphical approach to sequentially rejective multiple test proceduresStatistics in Medicine, 2008
- Finding a way out: lymphocyte egress from lymphoid organsNature Immunology, 2007
- Quality of life in patients with multiple sclerosisJournal of the Neurological Sciences, 2002
- Relapses and Progression of Disability in Multiple SclerosisNew England Journal of Medicine, 2000